PROGRAM CHAIRS
Matthew D. Galsky, MD, FASCO
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director, Genitourinary Medical Oncology
Associate Director, Translational Research
Tisch Cancer Institute
New York, NY
Ashish M. Kamat, MD, MBBS, FACS
Professor of Urologic Oncology (Surgery) and Cancer Research
Wayne B. Duddlesten Professor of Cancer Research
Department of Urology, Division of Surgery
Director, Bladder Cancer Research
University of Texas MD Anderson Cancer Center
Houston, TX
PROGRAM OVERVIEW
This interactive 2D online expert dialog program provides surgical urologists, urologists, uro-oncologists, medical oncologists, NPs/PAs, and nurses with critical updates on managing muscle-invasive bladder cancer (MIBC). Participants will examine the latest clinical evidence regarding antibody-drug conjugates (ADCs) and their expanding role in the MIBC treatment paradigm. Through case-based expert discussions and a 2D animation, the curriculum delivers practical strategies for early recognition, monitoring, and mitigation of ADC-associated adverse events. Additionally, the program emphasizes collaborative care, offering actionable frameworks to apply multidisciplinary and shared decision-making strategies that directly improve patient outcomes.
TARGET AUDIENCE
This activity has been designed to meet the educational needs of surgical urologists, urologists, uro-oncologists, medical oncologists, NPs/PAs, and nurses involved in the management of patients with bladder cancer.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Integrate the latest clinical evidence for ADCs and their role in managing MIBC
- Develop strategies for managing ADC-associated adverse events
- Apply multidisciplinary and shared decision-making strategies to improve patient outcomes
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hours.
AAPA Credit Designation Statement – Enduring Materials
Med Learning Group has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until June 26, 2027. PAs should only claim credit commensurate with the extent of their participation.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Matthew Galsky, MD, FASCO | Discloses receiving consulting fees from ABBVIE INC., AstraZeneca Pharmaceuticals LP, EMD Serono, Inc., Janssen Research & Development, LLC, Merck Sharp & Dohme LLC, and Pfizer Inc.; Travel support from ABBVIE INC., Janssen Research & Development, LLC., and Merck Sharp & Dohme LLC; Research funding from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dome LLC, Pfizer Inc., and Seagen |
| Ashish Kamat, MD, MBBS, FACS | Discloses receiving research funding from Arquer Diagnostics; EnGene, Ferring, PCORI, Photocure, Seagen, SWOG; Consulting fees from Astellas Pharma, Atonco Pharma, Biological Dynamic, Bristol-Myers Squibb, CG Oncology, Cystotech, Eisai, EnGene, Ferring, Genentech, Imagin Medical, ImmunityBio, Imvax, Incyte, Janssen (J&J), Medac, Merck, Nonagen Bioscience, Pfizer, Photocure, Protara Therapeutics, Roche, Seagen, Sesan Bio, Theralase, Urogen Pharma, US Biotest, Valar Labs, and Vivet Therapeutics |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Vaidehee Deshpande, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Shannon Mutch MS, RN, OCN, independent nursing review, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Marissa Mays-Verman, Program Director for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator, for Med Learning Group, has nothing to disclose.
- Stefani Rodriguez, Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Prior to participating, please contact Med Learning Group at [email protected]
RELEASED DATE: June 26, 2026
EXPIRATION DATE: June 26, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
